CRYSVITA
These highlights do not include all the information needed to use CRYSVITA safely and effectively. See full prescribing information for CRYSVITA. CRYSVITA (burosumab-twza) injection, for subcutaneous use Initial U.S. Approval: 2018
6f5f3556-3197-477a-993c-96b2c29a91ac
HUMAN PRESCRIPTION DRUG LABEL
Dec 16, 2022
Ultragenyx Pharmaceutical Inc.
DUNS: 962892019
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Burosumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (6)
Burosumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (7)
Burosumab
Product Details
FDA regulatory identification and product classification information